Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 31.15
(-0.16%)
TWD 31.15
(-0.16%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.96 Billion TWD | 3.72% |
| 2022 | 2.85 Billion TWD | 17.39% |
| 2021 | 2.43 Billion TWD | 1.89% |
| 2020 | 2.38 Billion TWD | -0.26% |
| 2019 | 2.39 Billion TWD | 8.07% |
| 2018 | 2.21 Billion TWD | 3.83% |
| 2017 | 2.13 Billion TWD | 0.03% |
| 2016 | 2.13 Billion TWD | -2.46% |
| 2015 | 2.18 Billion TWD | -17.21% |
| 2014 | 2.64 Billion TWD | 2.49% |
| 2013 | 2.57 Billion TWD | 23.54% |
| 2012 | 2.08 Billion TWD | 13.39% |
| 2011 | 1.84 Billion TWD | 0.97% |
| 2010 | 1.82 Billion TWD | 0.51% |
| 2009 | 1.81 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 769.32 Million TWD | -1.04% |
| 2024 Q1 | 777.39 Million TWD | 3.85% |
| 2023 FY | 2.96 Billion TWD | 3.72% |
| 2023 Q1 | 771.01 Million TWD | 1.12% |
| 2023 Q2 | 727.58 Million TWD | -5.63% |
| 2023 Q3 | 715.76 Million TWD | -1.63% |
| 2023 Q4 | 748.56 Million TWD | 4.58% |
| 2022 Q3 | 709.12 Million TWD | -0.99% |
| 2022 Q1 | 668.81 Million TWD | 4.28% |
| 2022 FY | 2.85 Billion TWD | 17.39% |
| 2022 Q4 | 762.5 Million TWD | 7.53% |
| 2022 Q2 | 716.2 Million TWD | 7.09% |
| 2021 Q4 | 641.34 Million TWD | 13.12% |
| 2021 Q3 | 566.94 Million TWD | -6.81% |
| 2021 FY | 2.43 Billion TWD | 1.89% |
| 2021 Q1 | 616.84 Million TWD | 14.13% |
| 2021 Q2 | 608.39 Million TWD | -1.37% |
| 2020 Q4 | 540.49 Million TWD | -15.48% |
| 2020 Q1 | 625.39 Million TWD | -6.87% |
| 2020 Q2 | 583.05 Million TWD | -6.77% |
| 2020 FY | 2.38 Billion TWD | -0.26% |
| 2020 Q3 | 639.51 Million TWD | 9.68% |
| 2019 Q4 | 671.53 Million TWD | 16.25% |
| 2019 Q3 | 577.66 Million TWD | 0.9% |
| 2019 FY | 2.39 Billion TWD | 8.07% |
| 2019 Q1 | 572.87 Million TWD | -4.28% |
| 2019 Q2 | 572.51 Million TWD | -0.06% |
| 2018 FY | 2.21 Billion TWD | 3.83% |
| 2018 Q2 | 529.34 Million TWD | -5.5% |
| 2018 Q1 | 560.12 Million TWD | -1.46% |
| 2018 Q4 | 598.47 Million TWD | 13.37% |
| 2018 Q3 | 527.9 Million TWD | -0.27% |
| 2017 Q1 | 508.08 Million TWD | -14.38% |
| 2017 Q4 | 568.45 Million TWD | 6.52% |
| 2017 Q3 | 533.63 Million TWD | 1.84% |
| 2017 FY | 2.13 Billion TWD | 0.03% |
| 2017 Q2 | 523.98 Million TWD | 3.13% |
| 2016 Q3 | 532.72 Million TWD | 5.28% |
| 2016 FY | 2.13 Billion TWD | -2.46% |
| 2016 Q4 | 593.4 Million TWD | 11.39% |
| 2016 Q2 | 506.01 Million TWD | 0.93% |
| 2016 Q1 | 501.36 Million TWD | -22.83% |
| 2015 FY | 2.18 Billion TWD | -17.21% |
| 2015 Q1 | 480.93 Million TWD | -31.41% |
| 2015 Q2 | 554.4 Million TWD | 15.28% |
| 2015 Q4 | 649.7 Million TWD | 29.33% |
| 2015 Q3 | 502.36 Million TWD | -9.39% |
| 2014 Q4 | 701.17 Million TWD | 40.35% |
| 2014 Q2 | 761.8 Million TWD | 12.1% |
| 2014 Q1 | 679.57 Million TWD | -4.68% |
| 2014 FY | 2.64 Billion TWD | 2.49% |
| 2014 Q3 | 499.59 Million TWD | -34.42% |
| 2013 Q1 | 485.48 Million TWD | -4.81% |
| 2013 Q3 | 755.87 Million TWD | 21.21% |
| 2013 Q4 | 712.93 Million TWD | -5.68% |
| 2013 FY | 2.57 Billion TWD | 23.54% |
| 2013 Q2 | 623.62 Million TWD | 28.45% |
| 2012 Q4 | 509.99 Million TWD | -6.94% |
| 2012 Q3 | 548.04 Million TWD | -1.08% |
| 2012 FY | 2.08 Billion TWD | 13.39% |
| 2012 Q2 | 554.03 Million TWD | 16.75% |
| 2012 Q1 | 474.55 Million TWD | -1.45% |
| 2011 Q2 | 451.17 Million TWD | -4.16% |
| 2011 Q1 | 470.75 Million TWD | -2.82% |
| 2011 Q3 | 436.8 Million TWD | -3.19% |
| 2011 Q4 | 481.53 Million TWD | 10.24% |
| 2011 FY | 1.84 Billion TWD | 0.97% |
| 2010 Q3 | 440.33 Million TWD | -7.67% |
| 2010 FY | 1.82 Billion TWD | 0.51% |
| 2010 Q1 | 420.99 Million TWD | 0.0% |
| 2010 Q4 | 484.4 Million TWD | 10.01% |
| 2010 Q2 | 476.91 Million TWD | 13.28% |
| 2009 FY | 1.81 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Apex Biotechnology Corp. | 1.67 Billion TWD | -76.729% |
| Panion & Bf Biotech Inc. | 1.88 Billion TWD | -57.446% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 2.08 Billion TWD | -42.009% |
| GenMont Biotech Incorporation | 318.01 Million TWD | -831.696% |
| Abnova (Taiwan) Corporation | 382.05 Million TWD | -675.532% |
| Adimmune Corporation | 1.78 Billion TWD | -65.982% |
| Tanvex BioPharma, Inc. | 61.41 Million TWD | -4724.761% |
| Polaris Group | 7.48 Million TWD | -39506.122% |
| Energenesis Biomedical CO.,LTD. | 7.15 Million TWD | -41293.322% |
| UnicoCell Biomed Co., Ltd. | 24.58 Million TWD | -11949.835% |
| PELL Bio-Med Technology Co. Ltd. | 18.03 Million TWD | -16330.622% |